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Abstract
Amyloid beta (Aβ) binding alcohol dehydrogenase (ABAD) is a cellular cofactor for promoting
(Aβ)-mediated mitochondrial and neuronal dysfunction, and cognitive decline in transgenic
Alzheimer's disease (AD) mouse models. Targeting mitochondrial ABAD may represent a novel
therapeutic strategy against AD. Here, we report the biological activity of small molecule ABAD
inhibitors. Using in vitro surface plasmon resonance (SPR) studies, we synthesized compounds
with strong binding affinities for ABAD. Further, these ABAD inhibitors (ABAD-4a and 4b)
reduced ABAD enzyme activity and administration of phosphonate derivatives of ABAD
inhibitors antagonized calcium-mediated mitochondrial swelling. Importantly, these compounds
also abolished Aβ-induced mitochondrial dysfunction as shown by increased cytochrome c
oxidase and adenosine-5′-triphosphate levels, suggesting protective mitochondrial function effects
of these synthesized compounds. Thus, these compounds are potential candidates for further
pharmacologic development to target ABAD to improve mitochondrial function.
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Introduction
Alzheimer's disease (AD) is a type of dementia in adults, which results in disordered
cognition and memory due to neuronal stress and subsequent cell death. Multiple reports
show that mitochondrial and synaptic dysfunction are early pathological features of AD
[1-6]. In AD, amyloid beta (Aβ) progressively accumulates in synaptic mitochondria
resulting in impaired mitochondrial structure and function [7-16]. Interaction of Aβ with
mitochondrial proteins such as cyclophilin D, a key component of mitochondrial
permeability transition pore, and Aβ-binding alcohol dehydrogenase (ABAD), a
mitochondrial enzyme, enhances mitochondrial oxidative stress, mitochondrial toxicity and
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cognitive decline [3; 7; 9; 17-24]. Thus, strategies that suppresses or attenuates Aβ-induced
mitochondrial toxicity in addition to decreasing Aβ levels in the brain may hold potential for
preventing and/or halting AD at its early stages by improving mitochondrial function.
Hence, development of substances that inhibit Aβ function may result in more effective
interventions for prevention and treatment interventions of AD. Scientists are exploring a
number of strategies to block Aβ including “secretase inhibitors” to block the secretase
clipping action [25-32]. It is not yet clear that any of these compounds will improve AD
symptoms or protect neuronal cells, and none have entered clinical trials due to continuing
concerns about side effects. Because AD is a multifaceted disease and its molecular biology
is poorly understood, multi-targeted approaches will likely yield more effective treatments.
As mitochondrial dysfunction is an early pathological feature of AD, targeting
mitochondrial function could be an effective therapeutic strategy.
ABAD, unique among members of the short-chain dehydrogenase reductase family as it
interacts with Aβ, has attracted considerable interest in AD drug discovery [9; 12; 33-36].
Increased ABAD expression was found in AD-affected brain regions (i.e., temporal gyrus
and hippocampus) but not in AD-spared regions (i.e., cerebellum) as compared to age-
matched, non-AD brain tissue [9; 37]. Similarly, transgenic (Tg) mice overexpressing
amyloid precursor protein (APP)/Aβ showed higher ABAD levels in AD-affected
hippocampus and cerebral cortex than nontransgenic littermate controls. Increased ABAD
expression results in exaggerated mitochondrial oxidative stress, abnormal energy
metabolism, and mitochondrial dysfunction in an AD mouse model [9; 12; 20; 38; 39]. Aβ
interaction with ABAD inhibits normal enzymatic activity of ABAD, thereby promoting
oxidative stress [9; 20], increasing mitochondrial toxicity [20], and inducing a signaling
cascade that leads to apoptosis and accelerates early deficits in learning and memory [9].
Interestingly, our recent studies indicate that inhibition of ABAD-Aβ interaction protects
mitochondria and neurons from Aβ-induced toxicity.
Recently, the search for inhibitors of ABAD-Aβ interactions has begun in the AD research
field. Using an ELISA-based screening assay, an FDA-approved immunosuppressant drug
called frentizole was identified as a novel inhibitor of ABAD-Aβ interactions. Analysis of
the frentizole structure-activity relationship (SAR) studies allowed Xie et al. to develop new
benzothiazole ureas with a 30-fold improvement in potency [33]. Previously, we designed
and synthesized eight ABAD inhibitors based on the frentizole and benzothiazole ureas SAR
studies; these inhibitors showed high affinity for binding to the human ABAD active site
[40]. In the present study, we first evaluated the ABAD inhibitor activity of these novel
benzothiazole phosphonate derivatives using in vitro surface plasmon resonance (SPR) to
determine whether the synthetic compounds bind to human recombinant ABAD protein.
Second, we examined the biological activity of these synthesized compounds on Aβ-induced
mitochondrial function. Based on our SPR binding studies and biological activity, we
selected these two compounds (i.e. 4a and 4b) for the present studies to characterize these
novel potent drugs for prevention and treatment of AD by improving mitochondrial and
neuronal function.
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Synthesis of ABAD inhibitors
We first synthesized the benzothiazole amino phosphonate derivatives using a three-
component reaction of equimolar quantities of aromatic aldehydes, 6-
methoxybenzo[d]thiazol-2-amine, and dimethyl phosphate in toluene at reflux temperature
in the presence of Mg (ClO4)2 [40]. In this study, we used the two best compounds that had
better biological activity based on binding affinity and effect on mitochondrial function
induced by calcium or Aβ from our recently published paper [40]. Compounds ABAD-4a
and 4b were in the form of white powder with melting points of 216°C and 180°C, and
molecular weights of 452 and 394, respectively. The Molecular formulae for compound 4a
is C19H22N2O7PS and for 4b is C17H19N2O5PS (Figure 1). High pressure liquid
chromatography (HPLC) purity of the compounds 4a and 4b was 98% and 100%,
respectively.
ABAD expression and purification
ABAD was produced recombinantly in Escherichia coli (BL21) and purified to
homogeneity as previously described [41]. Briefly, BL21 E. coli were transformed with
pGE5-human ABAD, prepared as described below. Transformants were induced with 0.5
mmisopropyl-1-thio-β-d-galactopyranoside for 3 h, and cell extracts were prepared by cell
disruption. Extracts were subjected to cation exchange fast protein liquid chromatography
(FPLC) chromatography on SP Sepharose Fast Flow (Amersham Pharmacia Biotech) and on
Source 15S, followed by gel filtration on Superdex 200. The extract from 1 liter of bacterial
culture was applied to 2 ml of SP Sepharose in 25 mM MES (pH 6.0), 50 mM NaCl, 5 mM
dithiothreitol. The resin was washed with equilibration buffer and eluted with an ascending
linear salt gradient (0.1–1.0 M NaCl).These fractions were pooled, diluted 6-fold, and
applied to Source 15S resin in 0.1 M MES (pH 6.0)/0.1 M NaCl (5 mg of protein per 1 ml of
resin). The column was eluted with an ascending salt gradient, and ABAD emerged at ≈0.15
M NaCl. ABAD-rich fractions were concentrated by ultrafiltration to ≈15 mg/ml and loaded
onto a Superdex 200 (30/10) column (1 ml was applied to the column for each run). Peak
fractions from Superdex 200 were subjected to immunoblotting for ABAD using specific
antibody to ABAD generated in our Lab and used in our previous study The ABAD
immunoreactive band was visualized at ≈27 kDa.
Binding Experiment with ABAD
We studied interactions between ABAD and compounds 4a and 4b using a dual flow cell as
described previously [7; 9]. SPR studies were performed on a BIACORE 3000 at 25°C. SPR
binding experiments with ABAD were performed in phosphate-buffered saline (PBS, pH
7.4, 0.005% surfactant P20), which served as both running and sample buffer. The surface of
the sensor chip was first activated with mixtures of N-hydroxysuccinimide (NHS, 115
mg/ml) and N-(3-dimethyl-aminopropyl)-N′-ethyl-carbodiimide-hydrochloride (EDC, 750
mg/ml) for 7 minutes. ABAD was dissolved in PBS buffer (pH 5.0) at a concentration of 10
μg/ml. The protein was immobilized directly and covalently on the hydrophilic carboxy
methylated dextran matrix of the CM5 sensor chip (Biacore) using the standard primary
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amine coupling reaction according to standard procedures. After protein immobilization,
excess activated carboxylic acid groups were quenched with ethanolamine (1 M, pH 8.5).
Care was taken during injection of samples to avoid carryover effects. Special washing
routines were used to clean the system before injection of new samples. Sample flow rate
was set at 40 μL/minute for the determination of the kinetic and equilibrium constant.
Regeneration of the surfaces between subsequent binding experiments was achieved by
washing the surface extensively with buffer solution.
All data analyses were carried out using BIA evaluation software, and sensor grams were
processed by automatic correction for nonspecific bulk refractive index effects. Kinetic
analyses of the ligand binding to the protein were performed based on the 1:1 Langmuir
binding fit model according to the standard procedures described in the software manual.
Assay of ABAD enzymatic activity
ABAD activity was determined by inhibition of reduction of S-acetoacetyl-CoA (SAAC).
The assay was carried out with human recombinant ABAD protein (418 ng/ml), SAAC (172
μM), NADH (102 μM), and a range of inhibitor concentrations (from 0 to 1000 μM) in 93
mM potassium phosphate buffer (pH 7.3) [41]. All assay components except SAAC were
pre-incubated for 5 min; the reaction was initiated with the addition of SAAC. The reaction
proceeded for 6 min at room temperature under steady-state conditions; the decrease NADH
absorbance at 340 nm was determined every 10 seconds. Kinetic data was analyzed using
PRISM software (Scitech, San Diego, CA) to determine IC50 value and Ki. One unit of
enzyme activity was defined as the amount needed to convert 1.0 μmol of substrate to
product per min.
Isolation of brain mitochondria
Brain cortex from mice without white matter was used for mitochondrial isolation.
Mitochondria were prepared as previously described [7; 42]. Briefly, brain cortical tissues
were homogenized in 9 ml of ice-cold EB buffer (EDTA 1 mmol, bovine serum albumin 1-6
mg/ml) using Dounce homogenizer until particles were no longer seen. Homogenates were
centrifuged at 1300 × g for 5 min. Supernatant from this fraction was carefully deposited on
top of 15% percoll solution (10 ml) and then centrifuged at 16000 RPM for 10 min. The
pellet was carefully mixed with 9 ml of mitochondrial buffer (D-mannitol 4.098%, Sucrose
2.56%, K2HPO4 0.034%, pH 7.3-7.4) and 200 μl of 1% digitonin. After 5 min incubation on
ice, the mixture was centrifuged at 8000 RPM for 10 min. The mitochondrial pellet was
resuspended in 100 μl of mitochondrial buffer and then used for further experiments.
Brain mitochondrial swelling and Calcium uptake/release inhibition assays
Appropriate amounts of mitochondria were re-suspended in 1 ml swelling assay buffer (150
mM KCl, 2 mM KH2PO4, 10 mM HEPES, pH 7.4) and energized with the addition of 1 mM
Glutamate and 1 mM Malate. Calcium (200 μM) was added to the assay buffer to trigger
mitochondrial swelling. Mitochondrial permeability transition was determined by measuring
the rate of change in absorbance at 540 nm on a spectrophotometer.
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Initial solubilization of Aβ peptide and preparation of oligomer Aβ
Aβ1-42 peptide (lyophilized powder, 1 mg, American Peptide Company, catalog number
62-0-8Q) was stored in sealed glass vials in desiccated containers at −80°C. Prior to
resuspension, the lyophilized peptide was allowed to equilibrate to room temperature for 30
min to avoid condensation. Under a chemical fume hood, lyophilized Aβ1-42 was
resuspended in 100% 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP, Sigma-Aldrich, catalog
number 105228) in a polypropylene vial using a glass GasTight® Hamilton syringe with a
Teflon plunger. After vortexing, the solution was divided between 3 polypropylene vials and
vortexed again. The HFIP was allowed to evaporate in the fume hood for 1 hour, and the
resultant clear peptide film was dried under vacuum (6.7 mTorr) in a SpeedVac centrifuge
for 10 minutes at 800 × g. The resulting pellet was stored desiccated at -20°C. Directly
before use, the aliquots were resuspended in 5 mM anhydrous dimethyl sulfoxide (DMSO,
Sigma-Aldrich, catalog number D-2650) by pipette mixing followed by bath sonication for
10 minutes.
Preparation of Aβ1-42 Oligomer [43]
Aβ1-42 oligomers were prepared by diluting 5 mM of Aβ1-42 aliquot in PBS, immediately
vortexing for 30 seconds, and incubated at 4°C for 24 hours. Prior to the experiment, the
aliquot was diluted in ice-cold culture media to the required concentration. We have
successfully prepared oligomer Aβ1-42 in our published studies [7; 15; 17; 44; 45]
Measurement of mitochondrial cytochrome c oxidase (CcO) activity
CcO activity was measured as described [3; 7] with a cytochrome c oxidase kit (Sigma). In
brief, human neuroblastoma (SK-N-SH) cells were incubated with ABAD inhibitor and Aβ
oligomer. After 48 hours incubation, cells were washed twice with PBS, followed by
harvesting of cell lysates. The protein concentration was determined by Bradford method.
Next, an appropriate volume of cells and enzyme solution was added to 475 μl of assay
buffer. The reaction was triggered by the addition of 25 μl freshly prepared ferrocytochrome
c substrate solution. Changes of OD550 nm were recorded immediately with an Amersham
Biosciences Ultrospec 3100 pro spectrophotometer programmed for 5 s delay, 10 s intervals
for a total of six readings.
Measurement of Adenosine-5′-triphosphate (ATP) level
ATP levels were determined using an ATP Bioluminesence Assay Kit (Roche) as our
previously described [7; 19]. Briefly, SK-N-SH cells were incubated with ABAD inhibitor
and oligomer Aβ1-42 at 37°C for 48 hours. Cells were harvested using ATP lysis buffer
followed by incubation for 30 minutes on ice. The mixture was centrifuged at 12,000 × g for
10 minutes at 4°C, and the supernatant was collected for the assay. The content of ATP was
measured according to the manufacturer's instructions [3; 7]. Light emitted from the
luciferase-mediated reaction was captured in a luminescence plate reader (Molecular
Devices) at 37°C with an integration time of 10 seconds and calculated from a log-log plot
of the standard curve of known ATP concentrations.
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Cell survival and toxicity assay
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium_bromide) assay, which is
widely used to measure cell proliferation and to screen for anticancer drugs, is used for
assessing cell viability. Cells were treated with a range of ABAD compounds (4a & 4b at 1,
10, 50, and 100 μM) for 48 hours and then subjected to MTT reduction assay following the
manufacture's instruction.
The trypan blue dye exclusion is commonly used for measuring cell viability and toxicity.
48-66 hours after treatment of ABAD compounds, the trypan blue exclusion experiments
were performed. In brief, cells plated in 96-well plates were washed with the balanced salt
solution (Hanks-Balanced Salts/HBSS) once, then replaced with HBSS including trypan
blue solution to the final concentration of 0.2% (Sigma-Aldrich, St. Louis, MO), and mixed
thoroughly. After stand at room temperature for 5 min, cells were washed HBSS again and
then maintained in the well with HBSS. Both the stained and unstained cells in each well
were counted under a microscope (Nikon E400). The calculated percentage of unstained
cells represented the percentage of viable cells. Cell viability (%) = total viable cells
(unstained)/ total cells (stained and unstained) ×100.
Statistical analysis
We performed statistical analyses with one-way analysis of variance (ANOVA) using the
Statview statistics software (SAS Institute, Version 5.0.1) with Bonferroni/Dumn posthoc
test. P<0.05 was considered significant. All data are expressed as means ± s.e.m.
Results
ABAD synthetic inhibitors bind to ABAD protein
We selectively synthesized two ABAD inhibitors based on our studies, which showed high
affinity of binding to human ABAD along with the improvement of mitochondrial function
(Fig. 1). We first evaluated the ABAD inhibitory activity of these synthetic compounds by
using in vitro SPR to determine whether synthetic compounds bind to human recombinant
ABAD protein. The Biacore sensor grams for the binding of compounds 4a and 4b to the
immobilized ABAD are shown in Figure 2. The 1:1 Langmuir binding fit model was used to
determine the equilibrium dissociation constant (KD), and the association (kon) and
dissociation (koff) rate constants by using Equations (1) and (2).
(1)
where R represents the response unit, C is the concentration of the analyte, and
(2)
These results were then evaluated by chi-square analysis. All kinetic parameters are listed in
Table 1.
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SPR results showed that both compounds 4a and 4b exhibited strong binding affinities for
ABAD (Figure 2) with KD values of 496 nM and 291 nM, respectively (Table 1).
Compound 4b exhibited slightly higher binding affinity with ABAD than 4a. This was
further verified by the ABAD enzymatic activity inhibition assay. These data indicate that
ABAD-4a and 4b compounds specifically target to ABAD with the highest affinity binding
properties of the synthesized compounds.
Effect on ABAD enzyme activity
To assess the effect of ABAD inhibitors on its enzymatic activity, we determined the ability
of the compounds to inhibition SAAC reduction by ABAD (Table 1 and Figure 3). ABAD
can catalyze a broad repertoire of substrates, including steroid hormones, fatty acids and
alcohols. Here, we utilized NADH-dependent SAAC reduction catalyzed by ABAD to
evaluate the inhibitors. By incubating varying concentrations of inhibitors with ABAD, we
determined the inhibitory effect on SAAC reduction. Compound 4b exhibited the most
potent inhibitory effect on SAAC reduction with IC50 at 52.7 μM and Ki at 14.9 μM.
Compound 4a showed modest inhibitory effect on SAAC reduction with IC50 at 341.9 μM
and Ki at 96.6 μM, whereas the previously reported human ABAD inhibitor (AG18051)
showed good inhibitory effect with IC50 at 92 nM when compared to compounds 4a and 4b.
Because enzymatic activity of ABAD is essential for potentiation of Aβ cytotoxicity, it is
possible that blocking Aβ–ABAD interaction with small-molecule inhibitors will, in turn,
decrease Aβ induced cytotoxicity. The effective concentration of ABAD compound 4a (1
μM) without toxicity is almost 100-fold lower than IC50 (96.6 μM) for inhibition of ABAD
activity, suggesting that compound 4a at 1μM would likely be therapeutic effects in AD.
Effect of ABAD inhibitors on mitochondrial function
Mitochondrial swelling in response to Ca2+—As ABAD plays a role in
mitochondrial dysfunction and since such dysfunction is relevant to Aβ accumulation and
oxidative stress in AD, we first evaluated the effect of the compounds 4a and 4b on
mitochondrial permeability transition pore (mPTP) formation. Cortical mitochondria were
isolated from mice and subjected to a swelling assay in response to calcium as previously
described [7; 18]. Mitochondria responded well to calcium-induced swelling compared to
vehicle-treated mitochondria. Addition of 4a or 4b significantly protected mitochondria from
calcium-induced swelling in a dose-dependent manner (Figure 4). Compound 4b was a more
potent inhibitor of calcium-induced mitochondrial swelling than 4a. The inhibitors did not
affect mitochondrial swelling without calcium, suggesting that the inhibitors have no effect
on mitochondrial physiology function (Figure 4).
CcO activity—To assess the effect of the inhibitors on Aβ-induced mitochondrial
respiratory function, we determined the activity of CcO, which is a key enzyme associated
with the mitochondrial respiratory chain. SK-N-SH cells were treated with 5 μM of oligomer
Aβ 1-42 in the presence of 1 μM inhibitor (4a or 4b, respectively) for 48 hours; samples
were then tested for CcO activity. Aβ treatment significantly decreased CcO activity,
whereas, addition of ABAD 4a- or 4b compounds rescued CcO activity in Aβ-treated cells
compared to vehicle-treated cells (Figure 5A-B). Inhibitor (4a or 4b) alone was without
effect on CcO activity in the absence of Aβ (Figure 5).
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Levels of ATP—To determine the effect of the ABAD inhibitors on Aβ-induced
impairment in energy metabolism, we measured ATP levels. SK-N-SH cells were exposed
to 5 μM of Aβ1-42 in the presence of 1μM of compound (4a or 4b, respectively). Then, we
measured ATP in cell lysates. As shown in Figure 6, Aβ treatment significantly decreased
ATP levels, whereas the addition of ABAD inhibitor rescued ATP activity. ATP levels in
cells exposed to ABAD inhibitors were comparable to those of vehicle-treated cells without
Aβ, suggesting no toxic effect of the inhibitors on mitochondrial energy metabolism. These
data suggest that ABAD inhibitors (4a-b) block mitochondrial dysfunction induced by Aβ
(Figure 6).
Effect of ABAD inhibitor on cell survival and toxicity—We evaluated the effect of
ABAD inhibitors on cell viability and toxicity using MTT reduction assay and trypan blue
exclusion, which are widely used to assess cell survival and toxicity and to screen for drugs
toxicity. Cells were treated with a range of concentrations of ABAD compound (4a and 4b)
at 1, 10, 50, 100 μM for 48 to 66 hours. Compared to vehicle treatment, cells treated with
ABAD compound did not reveal decreased MTT reduction (Fig. 7A), and increased
percentage of typan blue-positive cells (Fig. 7B), and abnormal morphology (Fig. 7C),
These data suggest that treatment of ABAD inhibitors alone do not have significant
cytotoxicity.
Discussion
Here, we evaluated the biological activities of two previously synthesized small molecule
ABAD inhibitors on ABAD enzymatic activity and the effects on mitochondrial swelling for
mPTP formation, Aβ-mediated abnormal mitochondrial respiratory function and bioenergy.
Interestingly, the substitution of methoxy at the 6-position in benzothiazole amine seems to
play a crucial role in phosphonate derivative bioactivity. Two benzothiazole phosphonates
(compounds 4a and 4b) inhibited ABAD enzymatic binding activity, reduced calcium-
induced mPTP formation, decreased Aβ-induced mitochondrial dysfunction, and increased
CcO and ATP levels. Clearly, the presence of the hydroxyl group on benzene at the 4-
position is essential for ABAD activity, which is consistent with the original design of
frentizole and benzothiazole urea scaffold as the active structure. Conversion of frentizole
into benzothiazole urea [33] or benzothiazole amino phosphonates [40] results in a
remarkable increase in ABAD enzymatic activity potency. Furthermore, the substitution of
the heterocyclic aldehyde at the amino position resulted in substantial loss of ABAD
inhibitory activity (data not shown).
When the 4-hydroxy substituent was constant, methoxy substitution at the 6-position of
benzothiazole amine was generally favorable for ABAD activity, conferring micromolar
IC50 values for enzymatic reaction inhibition. Furthermore, 6-methoxy-substituted
benzothiazole amine displayed potent enzymatic activity and a high therapeutic index. The
structurally simple 6-methoxy benzothiazole amine seems to be an optimal substitute for
ABAD binding, enzymatic, calcium induced swelling, mitochondrial respiratory function,
and energy metabolism inhibition comparable to frentizole and benzothiazole urea
derivatives. Additionally, modification of the phosphonate moiety benzthiazole ring has a
subtle effect on enzymatic potency (compound 4b). In contrast, benzothiazole phosphate
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analogues displayed an overall superior ABAD inhibitory effect in terms of the IC50 value
and therapeutic index. Thus, these studies shed new light on the design and understanding of
benzothiazole phosphate based enzyme inhibitors, which will be helpful for the evolution of
this scaffold into clinically useful AD drugs.
The results of our mitochondrial swelling assays indicated that the phosphonate derivatives
antagonize calcium-mediated mitochondrial swelling. The in vitro assays indicated that
compounds 4a and 4b inhibit calcium-dependent brain mitochondrial swelling and calcium
uptake and release. More importantly, these compounds largely diminished Aβ-induced
mitochondrial dysfunction as shown by increased CcO and ATP in addition to suppression
of calcium-induced mitochondrial swelling, demonstrating a protective effect of compounds
4a and 4b on mitochondrial function. The ABAD inhibitors alone did not affect normal
mitochondrial and neuronal function. Further, no changes in cell morphology, cell survival
and viability were found in cells treated with both ABAD compounds in which
concentration of ABAD inhibitor was even up to 100 μM, 100 fold higher than effective
dose (1μM), suggesting no toxic effects of the inhibitors on normal cellular function.
Since all assays have been carried out at different experimental conditions required, this
could be an explanation that the concentration of ABAD inhibitors depends on the
experimental condition. For example, we applied cell-free system to determine the direct
effect of the compound on ABAD activity under acute condition in an in vitro enzymatic
activity in which assays have to be completed in 10 min. In mitochondrial swelling assay,
mitochondria were isolated from brain tissue and then treated with calcium in vitro for 10-30
min under acute condition (25-100 μM ABAD compound), as compared with the assay to
determine the effect of Aβ on mitochondrial function in cell culture (48 hours) as shown in
Figures 5-6. In the experiments shown in Figures 5 and 6, we examined the effect of
compounds on mitochondrial function in cellular culture system. Our results clearly showed
the protective effect of compounds at 1μM on Aβ-induced mitochondrial dysfunction. The
results generated from 1μM compound are consistent with the data of the surface plasmon
resonance (SPR) with binding affinity (∼300-500 nM). Nevertheless, our studies
demonstrate that both compounds significantly improve mitochondrial function by increased
complex IV activity, a key enzyme associated with mitochondrial respiratory function, and
ATP production in Aβ-rich environment. These data provide the evidence for supporting the
conclusion on the protective effect of ABAD compound on Aβ-induced mitochondrial
injury.
Novelty of the present approach lies in the use of a phosphonate moiety, which can readily
penetrate biological membranes such as the blood-brain barrier and enter the target organ
[46-48]. Therefore, phosphate esters are commonly used for prodrug development and
exclusively used for water insoluble compounds. [46-50] Future plans include examination
of the ability of these compounds to cross the blood brain barrier and further evaluation of
the effects on mitochondrial and neuronal function, amyloid pathology, and behavior in an
AD mouse model. Additionally, we would like to examine whether our ABAD inhibitors are
able to reverse Aβ-initiated mitochondrial dysfunction by incubating neuronal cells with Aβ
prior to treatment with the 4a and 4b inhibitors.
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In summary, we identified benzthiazole phosphonates derivatives as ABAD inhibitors and
successfully developed new small molecule compounds that showed specific ligand binding
ability for ABAD. Furthermore, these ABAD inhibitors rescued mitochondrial function
diminished by calcium and Aβ. With the goal of improving mitochondrial function in AD,
these inhibitors hold potential for therapeutic development
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APP amyloid precursor protein
mPTP mitochondrial permeability transition pore
ATP Adenosine-5′-triphosphate
ABAD Amyloid binding alcohol dehydrogenase
Aß amyloid beta
AD Alzheimer's disease
SPR Surface plasmon resonance
CcO cytochrome c oxidase
SAR Structure–activity relationship
SAAC S-acetoacetyl-CoA
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The structures of the synthesized small molecule ABAD inhibitors 4a and 4b. Hit structures
of compounds 4a & 4b obtained by three component one pot reaction of 6-
methoxybenzo[d]thiazol-2-amine, aldehydes and dimethyl phosphonate. Compound
structures are shown three-dimensional orientation and chiral carbon represents with dashed
bonds. Solid lines represent bonds, which are in the plane of the paper and dashed lines to
represents bonds that are extend away from the viewer.
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The synthesized ABAD inhibitors, 4a (A) and 4b (B), bind to immobilized human
recombinant ABAD protein in a dose–dependent manner as shown by SPR. Globally fit data
(black lines) were overlaid with experimental data (red lines). Human recombinant ABAD
protein (10μg/ml) was immobilized directly on the hydrophilic carboxy methylated dextran
matrix of the CM5 sensor chip (Biacore) using the standard primary amine coupling reaction
according to standard procedures. Compounds (4a, 1, 2, 5, 10 μM & 4b, 1, 5, 10, 15 μM)
were injected at flow rate 40 μL/minute for the determination of the kinetic and equilibrium
constant. All data analyses were carried out using BIA evaluation software, and sensor
grams were processed by automatic correction for nonspecific bulk refractive index effects.
The dissociation constant (KD) was determined as indicated at 25°C
Valasani et al. Page 15























Inhibition of ABAD enzymatic activity in the presence of benzothiazole phosphonate
derivatives (small molecule ABAD inhibitors) 4a (A) and 4b (B). Human ABAD
recombinant protein (418 ng/ml) was incubated with or without ABAD compound 4a or 4b
(0-200 μM) in 93 mM potassium phosphate buffer (pH 7.3) containing NADH (102 μM).
Five minutes after incubation, SAAC were added to the reaction mixture. The reaction was
run for a total of 6 min. The decrease of NADH absorbance at 340 nm was determined every
10 seconds. Kinetic data was analyzed by PRISM software to determine IC50 value and Ki.
Both compounds (4a and 4b) significantly inhibited ABAD enzymatic activity using SAAC
substrate.
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Effect of Aβ/ABAD inhibitors [4a (A) and 4b(B)] on calcium-induced mitochondrial
swelling (red line) compared to vehicle-treated mitochondria (black). The isolated cortical
mitochondria (100 μg) were incubated with and without ABAD compound (4a or 4b) on ice
for 5 min. Calcium (200 μM) was added to the reaction buffer to trigger mitochondrial
swelling. The addition of the indicated concentrations of compounds (0 to 100 μM)
attenuated calcium-induced mitochondrial swelling.
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Effect of ABAD inhibitors (4a (A) and 4b (B)) on Aβ-induced reduction in CcO activity.
SK-N-SH cells were treated with 5μM oligomer Aβ plus the indicated inhibitor (4a or 4b) at
0.5 and 1μM, Aβ alone (5 μM), inhibitor alone (1μM), or vehicle without inhibitor,
respectively. After 48 hours, CcO activity was measured in cell lysates. *P<0.01 compared
to the indicated groups of vehicle, inhibitor (1μM) with Aβ, and inhibitor alone.
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Effect of ABAD inhibitors [4a (A) and 4b (B)] on Aβ-induced reduction of ATP levels. SK-
N-SH cells were exposed to 5μM oligomer Aβ plus the indicated inhibitor (4a or 4b) at 0.5
and 1μM, inhibitor alone (1μM), Aβ alone (5μM), or vehicle without inhibitor, respectively.
48 hours later, ATP levels were determined in cell lysates. *P<0.001compared to the
indicated groups of vehicle, inhibitor with Aβ, and inhibitor alone.
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Effect of ABAD inhibitors on cell survival and toxicity. SK-N-SH human neuronal cell line
was incubated with vehicle and ABAD compound (4a or 4b), respectively, at 37°C for 4 -66
hours, and then subjected to the MTT reduction to examine the cell survival (A) and typan
blue staining to assess cell death (B). The panel (C) showed the representative
morphological images with indicated treatment. The vehicle (0)-treated cells serviced as
controls. Scale bar = 50 μm.
Valasani et al. Page 20











































Valasani et al. Page 21
Table 1
ABAD enzymatic activity and SPR results.
ABAD Inhibitors ABAD enzymatic activity IC50 (μM) ABAD enzymatic activity Ki (μM) SPR KD (nM)
4a 341.89±68.68 96.6±19.4 496
4b 52.7±5.0 14.9±1.4 291
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